BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, August 3, 2026
View BioWorld MedTech
Home » Qiagen rolls out rapid, portable SARS-CoV-2 antigen test
To read the full article sign up for free or sign in.

Qiagen rolls out rapid, portable SARS-CoV-2 antigen test

Nov. 13, 2020
By Mary Ellen Schneider
Qiagen NV has started U.S. commercialization of a portable SARS-CoV-2 antigen testing device that can analyze up to 30 patient samples an hour. The Qiareach test features a portable hub device – smaller than a laptop – that can hold up to eight nasopharyngeal swab samples at a time. The test provides a digital readout of the results in two to 15 minutes – with strong positive results taking closer to two minutes and negative results coming back in 15 minutes.
Medical technology Diagnostics Coronavirus U.S.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 31, 2026.
  • Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors

    BioWorld Science
    Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
  • Silhouette illustration of DNA gene editing

    Death in Chinese gene-editing trial exposes ethical fault lines

    BioWorld
    The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
  • Anthony Fauci at Senate hearing 7-29

    Fauci’s silence may put him in contempt of Congress

    BioWorld
    After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
  • Mitochondria

    Seed funding at Adjuvia to treat mitochondrial dysfunction

    BioWorld Science
    Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing